Gosis et al. found that selective modulation of hepatic mTORC1 signaling through genetic deletion of Flcn and activation of transcription factor TFE3 affords selective inhibition of mTORC1 and protection against MASLD, respectively [42]. This evidence concerns the gene TFE3 and metabolic dysfunction-associated steatotic liver disease.